CSIMarket

Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

Eli Lilly's Suppliers Performance

LLY's Supply Chain

 
LLY Costs vs Sales of Suppliers Growth Eli Lilly's Suppliers recorded increase in sales by 15.79 % year on year in Q2 2022, sequentially sales grew by 2.18 %, Eli Lilly's cost of sales deteriorated by % year on year, compare to one quarter ago cost of sales fell by -30.96 % in Q2.

More on LLY Suppliers




Eli Lilly's Suppliers recorded increase in sales by 15.79 % year on year in Q2 2022, sequentially sales grew by 2.18 %, Eli Lilly's cost of sales deteriorated by -26.76 % year on year, compare to one quarter ago cost of sales fell by -30.96 % in Q2.

More on LLY Suppliers




Eli Lilly's Comment on Supply Chain


Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally have sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.

We produce most of our products in our own facilities. Our principal active ingredient manufacturing occurs at four owned sites in the U.S. as well as owned sites in Ireland, Puerto Rico, and the United Kingdom. Finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at a number of sites throughout the world. We utilize third parties for certain active ingredient manufacturing and finishing operations.

We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that should allow us to meet all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain a stable supply of our products, we take a variety of actions including a company-wide, comprehensive quality system, inventory management, and back-up sites.

However, human pharmaceutical and animal health production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.


Eli Lilly's Comment on Supply Chain


Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally have sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.

We produce most of our products in our own facilities. Our principal active ingredient manufacturing occurs at four owned sites in the U.S. as well as owned sites in Ireland, Puerto Rico, and the United Kingdom. Finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at a number of sites throughout the world. We utilize third parties for certain active ingredient manufacturing and finishing operations.

We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that should allow us to meet all expected product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand. To maintain a stable supply of our products, we take a variety of actions including a company-wide, comprehensive quality system, inventory management, and back-up sites.

However, human pharmaceutical and animal health production processes are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.



LLY's Suppliers Net Income grew by LLY's Suppliers Net margin fell in Q2 to
2.45 % 14.55 %


Eli Lilly And Company's Suppliers Sales Growth in Q2 2022 by Industry

Suppliers in Chemical Manufacturing Industry      27.85 %
Suppliers in Containers & Packaging Industry      11.72 %
Suppliers in Miscellaneous Manufacturing Industry      7.38 %
Suppliers in Industrial Machinery and Components Industry      9.11 %
Suppliers in Food Processing Industry      12.81 %
Suppliers in Environmental Services Industry      1.06 %
Suppliers in Communications Equipment Industry      3.26 %
Suppliers in Scientific & Technical Instruments Industry      18.3 %
     
• LLY Suppliers Valuation • LLY Segment Rev. Growth • LLY Segment Inc. Growth • LLY Suppliers Mgmt. Effect.





LLY's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Eli Lilly And Company 275,023.34 29,070.70 5,691.60 33,625
Cryoport inc. 1,893.15 229.59 -297.19 31
Avery Dennison Corporation 16,199.15 8,951.30 759.50 30,000
Stericycle Inc. 4,822.06 2,650.20 -85.90 16,718
Darling Ingredients Inc 12,203.65 5,060.99 694.60 10,000
Medidata Solutions Inc 5,751.95 684.56 44.05 1,680
Veeva Systems Inc. 35,956.11 1,978.36 430.55 2,171
Bemis Co Inc 5,239.24 4,063.90 238.50 19,100
Corning Inc 31,382.98 14,586.00 2,023.00 50,110
Dow Inc. 38,564.68 60,129.00 6,700.00 35,700
Eastman Chemical Co 12,349.79 10,912.00 1,227.00 14,500
Scully Royalty Ltd 143.27 54.61 5.94 0
Piedmont Lithium Inc 806.17 0.00 160.56 10,400
Sigma Aldrich Corp 0.00 4,724.00 491.00 9,300
Thermo Fisher Scientific Inc. 233,271.64 42,820.00 7,451.00 75,000
Waters Corp 24,913.58 -1,134.84 593.79 7,500
Atyr Pharma Inc 103.76 10.46 -38.78 0
Illinois Tool Works Inc 66,466.31 15,185.00 2,648.00 44,000
Air Products And Chemicals Inc. 59,064.85 11,969.70 2,292.30 19,275
Fmc Corporation 13,835.26 5,410.70 690.40 6,400
Airgas Inc 0.00 0.00 0.00 17,000
Danaher Corporation 214,286.40 30,816.00 6,351.00 60,000
Ashland Global Holdings Inc. 153.90 2,084.00 913.00 11,000
Om Group Inc 0.00 1,103.18 -80.16 6,200
Synalloy Corporation 137.05 381.16 29.41 411
Albemarle Corporation 28,802.35 4,332.09 358.18 6,000
Chemtura Corp 0.00 1,462.00 -893.00 2,500
Huntsman Corporation 6,054.75 9,343.00 1,314.00 15,000
Quaker Chemical Corporation 3,371.14 1,862.67 83.39 2,020
Omnova Solutions Inc 455.29 722.90 -21.70 2,100
Stepan Company 2,534.90 2,639.62 150.92 2,073
Westlake Corporation 12,507.28 15,101.00 2,918.00 8,870
Westlake Chemical Partners Lp 888.00 1,525.87 398.18 141
Barnes Group Inc 1,698.96 1,278.49 40.94 5,036
Trecora Resources 231.52 301.32 8.99 310
Photronics Inc. 1,389.21 746.27 127.74 1,475
SUBTOTAL 835,478.36 261,985.08 37,727.21 492,021
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

LYV's Profile

Stock Price

LYV's Financials

Business Description

Fundamentals

Charts & Quotes

LYV's News

Suppliers

LYV's Competitors

Customers & Markets

Economic Indicators

LYV's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071